Dublin, June 14, 2018 (GLOBE NEWSWIRE) -- The "Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering.
The Viral Vectors and Plasmid DNA Manufacturing Market (2nd Edition), 2018-2030 report offers a comprehensive study of the current scenario of manufacturing of viral and non-viral vectors that are primarily used for the development of gene therapies and T-cell therapies. The study features an in-depth analysis, highlighting the capabilities of a diverse set of players, covering both contract manufacturers and companies with in-house capabilities.
Genetically modified therapies have emerged as a promising treatment option for various diseases (primarily ones that currently have no cure), including cancers, inherited disorders and certain viral infections. These therapies have demonstrated the potential to treat chronic indications, such as Alzheimer's disease, Parkinson's disease and rheumatoid arthritis, as well. Gene therapies, and other therapies that require genetic modification, involve the introduction of therapeutic DNA / gene of interest into a patient's body / cells. This process is accomplished by the use of vectors. Over the last few decades, various viral and non-viral vectors have been developed, optimized and standardized for this purpose.
Currently, the most popular viral vectors, on the basis of their use in active clinical trials, are those based on AAV, adenovirus, lentivirus and retrovirus. On the other hand, among non-viral gene delivery tools, plasmid DNA has emerged as the preferred option. Plasmid DNA is also used in the development and production of viral vectors and DNA vaccines. Recent advances have led to the emergence of several other innovative viral / non-viral gene delivery approaches that are being utilized for development of various therapies that require gene modification.
Overall, eleven genetically modified therapies have been approved so far; these are (in the order of approval, most recent first) LUXTURNA, YESCARTA, Kymriah, INVOSSA, Zalmoxis, Strimvelis, Imlygic, Neovasculagen, Rexin-G, Oncorine and Gendicine. Amongst these, YESCARTA and Kymriah are T-cell based gene therapies that were recently approved by the FDA, in October 2017 and August 2017, respectively.
In addition, over 430 gene therapy candidates are presently in different stages of clinical development, for which over 500 clinical studies are currently underway in various regions across the globe. The growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, is expected to continue to create an increasing demand for vectors.
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral and Non-Viral Methods of Gene Transfer
3.3. Viral Vectors for Genetically Modified Therapies
3.4. Type of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.5.5. Methods of Gene Delivery using Non-Viral Vectors: Methods of Transfection
3.5.5.1. Biolistic Methods
3.5.5.2. Electroporation
3.5.5.3. Receptor Mediated Gene Delivery
3.5.5.4. Gene Activated Matrix (GAM)
3.6. Applications of Viral and Non-Viral Vectors
3.6.1. Type of Therapy
3.6.1.1. Gene Therapy
3.6.1.2. Vaccinology
3.6.2. Current Trends in Vector Development / Manufacturing
3.6.2.1. Vector Engineering: Synthetic and Next Generation Vectors
3.6.2.2. Cargo Engineering
4. VIRAL VECTOR MANUFACTURERS: COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Viral Vectors Manufacturers: Overall Market Landscape
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Location of Manufacturing Facility
4.2.3. Distribution by Type of Organization
4.2.4. Distribution by Purpose of Production
4.2.5. Distribution by Type of Vector
4.2.6. Distribution by Scale of Production
5. PLASMID DNA MANUFACTURERS: COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Plasmid DNA Manufacturers: Overall Market Landscape
5.2.1. Distribution by Year of Establishment
5.2.2. Distribution by Location of Manufacturing Facility
5.2.3. Distribution by Type of Organization
5.2.4. Distribution by Purpose of Production
5.2.5. Distribution by Scale of Production
6. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN NORTH AMERICA
6.1. Chapter Overview
6.2. Aldevron
6.3. BioReliance / SAFC Commercial (Merck KGaA)
6.4. bluebird bio
6.5. Brammer Bio
6.6. FUJIFILM Diosynth Biotechnologies
6.7. MassBiologics
6.8. Novasep
6.9. Spark Therapeutics
6.10. Vigene Biosciences
7. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN EUROPE
7.1. Chapter Overview
7.2. Biovian
7.3. Cell and Gene Therapy Catapult
7.4. Cobra Biologics
7.5. FinVector
7.6. Kaneka Eurogentec
7.7. Lonza
7.8. MolMed
7.9. Oxford BioMedica
7.10. Richter-Helm
7.11. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
7.12. uniQure
7.13. VIVEbiotech
8. VIRAL VECTORS AND PLASMID DNA MANUFACTURING IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Wuxi AppTec
8.3. Other Key Players
9. EMERGING VECTORS
9.1. Chapter Overview
9.1.1. Alphavirus Based Vectors
9.1.2. Bifidobacterium longum (B. longum) Based Vectors
9.1.3. Cytomegalovirus (CMV) Based Vectors
9.1.4. Listeria Monocytogenes Based Vectors
9.1.5. Minicircle DNA Based Vectors
9.1.6. Myxoma Virus Based Vectors
9.1.7. Self-Complementary Vectors
9.1.8. Sendai Virus Based Vectors
9.1.9. Sleeping Beauty Transposons
10. RECENT COLLABORATIONS AND PARTNERSHIPS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Viral Vectors and Plasmid DNA Manufacturing: Recent Collaborations and Partnerships
10.4. Other Collaborations
11. KEY INSIGHTS
11.1. Chapter Overview
11.2. Viral Vectors and Plasmid DNA Manufacturers: Competitive Landscape by Vector Type, Scale of Operation and Purpose of Manufacturing
11.3. Viral Vectors and Plasmid DNA Manufacturers: Logo Landscape by Vector Type and Size of the Company
11.4. Viral Vectors and Plasmid DNA Manufacturers: Prominent Geographical Hubs by Type of Manufacturer
11.4.1. Contract Manufacturers
11.4.2. In-House Manufacturers
11.5. Viral Vectors and Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility and Type of Vector
11.5.1. AAV Vector Manufacturers
11.5.2. Adenoviral Vector Manufactures
11.5.3. Lentiviral Vector Manufactures
11.5.4. Retroviral Vector Manufactures
11.5.5. Plasmid DNA Manufactures
12. VIRAL VECTORS AND PLASMID DNA: COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Viral Vectors and Plasmid DNA Based Therapies (Genetically Modified Therapies): Factors Contributing to Higher Price Tags
12.3. Viral Vectors and Plasmid DNA Prices
12.3.1. Based on Expert Opinions
12.3.2. Based on Manufacturing Cost
12.3.2.1. Based on Technology Used
12.3.2.2. Based on Scale of Manufacturing
12.3.2.3. Based on Client Type
12.3.3. Price Points on Different Types of Vectors
12.4. Concluding Remarks
13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Viral Vectors Manufacturing: Installed Global Capacity
13.4. Plasmid DNA Manufacturing: Installed Global Capacity
13.5. Viral Vectors and Plasmid DNA Manufacturing: Overall Installed Global Capacity
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope of the Forecast
14.3. Forecast Methodology
14.4. Input Tables and Key Assumptions
14.5. Overall Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030
14.5.1. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Vector Type (AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA, Other Viral Vectors)
14.5.2. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Application (Gene Therapy / T-cell Therapy)
14.5.3. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Therapeutic Area (Oncology, Inflammation & Immunology, Ophthalmology, Metabolic Disorders, Cardiovascular Disorders, Others)
14.5.4. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Scale of Operation (Clinical / Commercial)
14.5.5. Viral Vectors and Plasmid DNA Manufacturing Market, 2018-2030: Distribution by Geography (North America, Europe, Asia-Pacific, RoW)
14.6. Opportunity from Commercial Products
14.6.1. AAV Vectors
14.6.2. Adenoviral Vectors
14.6.3. Lentiviral Vectors
14.6.4. Retroviral Vectors
14.6.5. Plasmid DNA
14.6.6. Other Viral Vectors
14.7. Opportunity from Clinical Products
14.7.1. AAV Vectors
14.7.2. Adenoviral Vectors
14.7.3. Lentiviral Vectors
14.7.4. Retroviral Vectors
14.7.5. Plasmid DNA
14.7.6. Other Viral Vectors
15. DRIVERS AND CHALLENGES
15.1. Chapter Overview
15.2. Viral Vectors and Plasmid DNA: Drivers and Challenges
15.2.1. AAV Vectors
15.2.2. Adenoviral Vectors
15.2.3. Lentiviral Vectors
15.2.4. Retroviral Vectors
15.2.5. Plasmid DNA
15.3. Additional Information
16. SURVEY ANALYSIS
16.1. Chapter Overview
16.2. Seniority Level of Respondents
16.3. Type of Vector
16.4. Scale of Production
16.5. Vector Stabilization Technology
16.6. In-house / Contract Operations
17. CONCLUSION
17.1. Increasing Efforts Related to Development of Advanced Therapy Candidates that Require Genetic Manipulation have Led to a Rise in the Demand for Vectors
17.2. Manufacturing Efforts in this Domain Feature the involvement of Several Industry Players and Academic Institutes; Many Startups have also been Established in the Recent Past
17.3. Given Regulatory Stringencies and Exorbitant Costs Associated with Developing In-House Facilities, Outsourcing Has Emerged as a Reliable Option for Vector Manufacturing
17.4. Manufacturers Have Established their Presence Across Different Regions; the US and EU have Emerged as Key Hubs
17.5. Several Efforts to Develop Innovative Technology Platforms are Underway, and are Expected to Drive the Production of Efficient, Safe and Stable Vectors
17.6. Novel Viral and Bacterial Strains are Being Investigated as Vectors for use in Genetically Modified Therapies / Vaccines
17.7. The Partnership Activity in this Domain is on the Rise as Companies Actively Collaborate to Develop Innovative Manufacturing Technology Platforms
17.8. Driven by a Rapidly Evolving Pipeline of Therapies, the Market is Anticipated to Grow at an Accelerated Pace over the Coming Decade
18. EXECUTIVE INSIGHTS
18. Executive Insights
18.1. Chapter Overview
18.2. Amsterdam BioTherapeutics Unit (AmBTU)
18.2.1. Overview of the Organization
18.2.2. Interview Transcript: Joost van den Berg, Director
18.3. ACGT
18.3.1. Overview of the Organization
18.3.2. Interview Transcript: Semyon Rubinchik, Scientific Director
18.4. CEVEC Pharmaceuticals
18.4.1. Overview of the Organization
18.4.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
18.5. Clean Cells
18.5.1. Overview of the Organization
18.5.2. Interview Transcript: Laurent Ciavatti, Business Development Manager, Olivier Boisteau, President / Co-Founder and Xavier Leclerc, Head of Gene Therapy
18.6. CJ PARTNERS
18.6.1. Overview of the Organization
18.6.2. Interview Transcript: Interview Transcript, Colin Lee Novick, Managing Director
18.7. Delphi Genetics
18.7.1. Overview of the Organization
18.7.2. Interview Transcript: Cedric Szpirer, Executive & Scientific Director
18.8. GEG Tech
18.8.1. Overview of the Organization
18.8.2. Interview Transcript: Nicolas Grandchamp, R&D Leader
18.9. MGH Viral Vector Development Facility, Massachusetts General Hospital
18.9.1. Overview of the Organization
18.9.2. Interview Transcript: Bakhos A Tannous, Director
18.10. Novasep
18.10.1. Overview of the Organization
18.10.2. Interview Transcript: Alain Lamproye, President of Biopharma Business Unit
18.11. Richter-Helm
18.11.1. Overview of the Organization
18.11.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
18.12. Plasmid Factory
18.12.1. Overview of the Organization
18.12.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Marketing Manager
18.13. Vigene Biosciences
18.13.1. Overview of the Organization
18.13.2. Interview Transcript: Jeffrey Hung, Chief Commercial Officer
18.14. Waisman Biomanufacturing
18.14.1. Overview of the Organization
18.14.2. Interview Transcript: Brian M Dattilo, Business Development Manager
For more information about this report visit https://www.researchandmarkets.com/research/vrg6q3/global_viral?w=12